Educational content only. Not medical advice. Consult a qualified physician.
Follistatin peptide
Growth HormoneResearch-only for peptide form. Gene therapy approaches (AAV-FS344) have entered early clinical trials for inclusion body myositis and muscular dystrophy. Not FDA-approved as a peptide therapeutic.

Follistatin

Follistatin is a naturally occurring glycoprotein that binds and neutralizes members of the TGF-beta superfamily, particularly myostatin (a negative regulator of muscle growth) and activin. By inhibiting myostatin, follistatin may promote muscle growth and development. Various isoforms exist, with Follistatin-344 being the most commonly referenced in research contexts.
Reported Benefits

Potential Benefits

  • Research confirms follistatin's role as a myostatin inhibitor, which may support muscle growth
  • Animal studies (including gene therapy approaches) demonstrate increased muscle mass
  • May support muscle preservation and recovery based on preclinical data
  • Research suggests roles in reproductive health and follicular development
  • Preclinical data indicates potential applications in muscular dystrophy
Research Dosing

Recommended Starting Dose

100 mcg subcutaneously (highly experimental; no established clinical dose)

Based on published research protocols. Not a prescription.

Dosing Protocol

No established clinical dosing protocol. Research and anecdotal protocols vary. Some sources describe 100 mcg subcutaneously daily for 10-30 days. Gene therapy approaches (AAV-follistatin) have been studied in muscular dystrophy clinical trials at academic centers. This remains a highly experimental area.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Anecdotal reports suggest potential effects on strength and recovery within 2-4 weeks. No validated human timeline data exists for exogenous peptide administration.

Regulatory

Research Status

Research-only for peptide form. Gene therapy approaches (AAV-FS344) have entered early clinical trials for inclusion body myositis and muscular dystrophy. Not FDA-approved as a peptide therapeutic.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Very limited human data for exogenous follistatin administration
  • Potential effects on reproductive hormones (activin/inhibin balance)
  • Theoretical concerns about uncontrolled tissue growth
  • Joint and tendon strain from rapid muscle development (theoretical)
  • Quality control concerns with commercially available products
  • Long-term safety is not established
Related Research

More in Growth Hormone

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.